Mehmet SATAR, Ali Kemal TOPALOĞLU, Ferda ÖZLÜ, İnci BATUN, Kadir ORTAKÖYLÜ, Hacer Y YILDIZDAŞ, Hüsnü DEMİR

Gebelikte annenin karbamezepin ve valproik asit kullanımına bağlı hipomagnesemi ve çekilme sendromu

Gebelik döneminde kullanılan ilaçlar fetüsü ve yenidoğanı etkilemektedir. Bu yazıda, gebeliği süresince epilepsi tanısı ile valproik asit ve karbamazepin kullanan bir annenin yenidoğan bebeğinde gözlenen bulgular sunuldu. Olguda bu ilaçların kullanımına bağlı olduğu düşünülen hiponatremi, beslenme sorunu, çekilme sendromu bulguları ile birlikte hipomagnezemi ve 4 mm çapında atriyal septal defekt saptandı. Gebelikte karbamazepin ve valproik asit kullanımına bağlı birçok yan etki bildirilmiştir. Bu ilaçların gebelikteki kullanımlarına bağlı bilinen yan etkilerine ek olarak bilgilerimize göre hipomagnezemi bulgusu daha önce bildirilmemiştir. Bebekte saptanan hipomagnezeminin bu ilaçların kullanımına bağlı olduğu düşünüldü.

Withdrawal syndrome and hypomagnesaemia and in a newborn exposed to valproic acid and carbamazepine during pregnancy

The usage of drugs during pregnancy affect the fetus and the newborn. In this report, we present findings from a newborn baby, whose mother was epileptic, and was under the treatment of valproic acid and carbamazepine during pregnancy. We have found symptoms of withdrawal syndrome, hyponatremia and feeding problem, which was most probably related to exposure to the mentioned drugs. We have also diagnosed hypomagnesaemia and atrial septal defect 4 milimeters in diameter. There are already many reports about the side effects of valproic acid and carbamazepine usage during pregnancy. To the best of our knowledge, hypomagnesaemia has not yet been reported as a side effect. We think that hypomagnesaemia is also related to the usage of antiepileptics.

PDF

___

1. Ambrósio AF, da-Silva PS, Carvalho CM, et al. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochemical Research 2002; 27: 121-30. [CrossRef ]
2. Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011; 305: 1996-2002. [CrossRef ]
3. Elshama SS, Osman HE, El-Kenawy Ael-M, et al. Teratogenic effect of carbamazepine use during pregnancy in the mice. Pak J Pharm Sci 2015; 28: 201-2
4. Chandane PG, Shah I. Fetal valproate syndrome. Indian J Hum Genet 2014; 20: 187-8 [CrossRef ]
5. Zimmermann-Baer U, Nötzli U, Rentsch K, et al. Finnegan neonatal abstinence scoring system: normal values for first 3 days and weeks 5-6 in non-addicted infants. Addiction 2010; 105, 524-8. [CrossRef ]
6. Karataş Z, Karataş A, Özlü T, et al. Bicuspid aortic valve and severe aortic stenosis in a newborn exposed to carbamazapine during pregnancy. J Turk Ger Gynecol Assoc 2014; 15: 259-61. [CrossRef ]
7. Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014; 10: CD010236. [CrossRef]
8. Rodríguez-Pinilla E, Mejías C, Prieto-Merino D, et al. Risk of hypospadias in newborn infants exposed to valproic acid during the first trimester of pregnancy: a case-control study in Spain. Drug Saf 2008; 31: 537-43. [CrossRef ]
9. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010; 362: 2185-93. [CrossRef ]
10. Çoban D, Kurtoğlu S, Akın MA, Akçakuş M, Güneş T. Neonatal episodic hypoglycemia: a finding of valproic acid withdrawal. J Clin Res Pediatr Endocrinol 2010; 2: 92-4.[CrossRef ]